{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Allogeneic+transplantation&page=3", "query": { "intervention": "Allogeneic transplantation", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 2211, "total_pages": 222, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Allogeneic+transplantation&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Allogeneic+transplantation&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-04T02:31:17.882Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00278512", "title": "Hematopoietic Stem Cell Support in Vasculitis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Vasculitis" ], "interventions": [ { "name": "Autologous Stem Cell Transplant", "type": "BIOLOGICAL" }, { "name": "Allogeneic Stem Cell Transplant", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "ATG (rabbit)", "type": "DRUG" }, { "name": "G-CSF", "type": "DRUG" }, { "name": "Campath-1h", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "16 Years to 60 Years" }, "enrollment_count": 7, "start_date": "2003-08", "completion_date": "2016-06", "has_results": true, "last_update_posted_date": "2018-08-02", "last_synced_at": "2026-10-04T02:31:17.882Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00278512" }, { "nct_id": "NCT05909202", "title": "A Nature-Based Virtual Reality (VR) Intervention in Family Caregivers of Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Neoplasm", "Caregivers" ], "interventions": [ { "name": "Sham VR", "type": "DEVICE" }, { "name": "Active VR", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "National Institutes of Health Clinical Center (CC)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 28, "start_date": "2024-06-05", "completion_date": "2026-02-27", "has_results": false, "last_update_posted_date": "2026-04-20", "last_synced_at": "2026-10-04T02:31:17.882Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05909202" }, { "nct_id": "NCT00325741", "title": "Allogeneic Blood Stem Cell Transplantation for Patients With Life-Threatening Systemic Lupus Erythematosus", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lupus Erythematosus, Systemic" ], "interventions": [ { "name": "Hematopoietic Cell Transplantation", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 1, "start_date": "2004-06", "completion_date": "2015-10", "has_results": false, "last_update_posted_date": "2023-08-15", "last_synced_at": "2026-10-04T02:31:17.882Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00325741" }, { "nct_id": "NCT00611702", "title": "Genomics of Chronic Renal Allograft Rejection (The GoCAR Study)", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Kidney Transplantation" ], "interventions": [ { "name": "Kidney biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 588, "start_date": "2008-06", "completion_date": "2013-07", "has_results": false, "last_update_posted_date": "2015-05-14", "last_synced_at": "2026-10-04T02:31:17.882Z", "location_count": 4, "location_summary": "Chicago, Illinois • Ann Arbor, Michigan • New York, New York + 1 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT00611702" }, { "nct_id": "NCT03641677", "title": "Increasing Lung Transplant Availability Using Normothermic Ex Vivo Lung Perfusion (EVLP) at a Dedicated EVLP Facility", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Lung Diseases" ], "interventions": [ { "name": "Centralized Lung Evaluation System", "type": "DEVICE" }, { "name": "Lung Transplant", "type": "PROCEDURE" } ], "intervention_types": [ "DEVICE", "PROCEDURE" ], "sponsor": "Lung Bioengineering Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 174, "start_date": "2019-04-21", "completion_date": "2024-01-18", "has_results": true, "last_update_posted_date": "2026-09-03", "last_synced_at": "2026-10-04T02:31:17.882Z", "location_count": 13, "location_summary": "Jacksonville, Florida • Atlanta, Georgia • Baltimore, Maryland + 9 more", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03641677" }, { "nct_id": "NCT02122081", "title": "Organ-Sparing Marrow-Targeted Irradiation Before Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Acute Lymphoblastic Leukemia in Remission", "Adult Acute Myeloid Leukemia in Remission", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Del(5q)", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "de Novo Myelodysplastic Syndromes", "Previously Treated Myelodysplastic Syndromes", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Secondary Myelodysplastic Syndromes", "Untreated Adult Acute Lymphoblastic Leukemia", "Untreated Adult Acute Myeloid Leukemia" ], "interventions": [ { "name": "radiation therapy", "type": "RADIATION" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "anti-thymocyte globulin", "type": "BIOLOGICAL" }, { "name": "tacrolimus", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "allogeneic bone marrow transplantation", "type": "PROCEDURE" }, { "name": "allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "RADIATION", "DRUG", "BIOLOGICAL", "PROCEDURE", "OTHER" ], "sponsor": "Sumithira Vasu", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 33, "start_date": "2015-07-27", "completion_date": "2022-09-06", "has_results": false, "last_update_posted_date": "2023-09-21", "last_synced_at": "2026-10-04T02:31:17.882Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02122081" }, { "nct_id": "NCT03112603", "title": "A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Graft-versus-host Disease (GVHD)" ], "interventions": [ { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Extracorporeal photopheresis (ECP)", "type": "DRUG" }, { "name": "Low-dose methotrexate (MTX)", "type": "DRUG" }, { "name": "Mycophenolate mofetil (MMF)", "type": "DRUG" }, { "name": "mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus)", "type": "DRUG" }, { "name": "Infliximab", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Pentostatin", "type": "DRUG" }, { "name": "Imatinib", "type": "DRUG" }, { "name": "Ibrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 330, "start_date": "2017-06-29", "completion_date": "2022-12-15", "has_results": true, "last_update_posted_date": "2025-08-12", "last_synced_at": "2026-10-04T02:31:17.882Z", "location_count": 38, "location_summary": "Tucson, Arizona • Duarte, California • La Jolla, California + 28 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT03112603" }, { "nct_id": "NCT06799195", "title": "Optimizing GVHD Prophylaxis After Allogeneic Hematopoietic Cell Transplantation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hematological Malignancies", "Graft-versus-Host Disease (GVHD)" ], "interventions": [ { "name": "Attenuated-dose Cyclophosphamide", "type": "DRUG" }, { "name": "High-dose Cyclophosphamide", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Mycophenolate Mofetil (MMF)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Nebraska", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 126, "start_date": "2025-06-23", "completion_date": "2031-11", "has_results": false, "last_update_posted_date": "2025-12-15", "last_synced_at": "2026-10-04T02:31:17.882Z", "location_count": 1, "location_summary": "Omaha, Nebraska", "locations": [ { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT06799195" }, { "nct_id": "NCT06472453", "title": "Vallomix Socket Preservation Study", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Alveolar Ridge Augmentation" ], "interventions": [ { "name": "Allograft/Xenograft", "type": "DEVICE" }, { "name": "Allograft", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "University of Maryland, Baltimore", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2025-01-13", "completion_date": "2028-06", "has_results": false, "last_update_posted_date": "2026-02-10", "last_synced_at": "2026-10-04T02:31:17.882Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06472453" }, { "nct_id": "NCT00060372", "title": "Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative", "Childhood Myelodysplastic Syndromes", "Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Disseminated Neuroblastoma", "Malignant Neoplasm", "Ovarian Choriocarcinoma", "Ovarian Embryonal Carcinoma", "Ovarian Immature Teratoma", "Ovarian Mature Teratoma", "Ovarian Mixed Germ Cell Tumor", "Ovarian Monodermal and Highly Specialized Teratoma", "Ovarian Polyembryoma", "Ovarian Yolk Sac Tumor", "Previously Treated Myelodysplastic Syndromes", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Malignant Testicular Germ Cell Tumor", "Recurrent Mantle Cell Lymphoma", "Recurrent Neuroblastoma", "Recurrent Ovarian Epithelial Cancer", "Recurrent Ovarian Germ Cell Tumor", "Refractory Chronic Lymphocytic Leukemia", "Refractory Multiple Myeloma", "Relapsing Chronic Myelogenous Leukemia", "Stage I Multiple Myeloma", "Stage II Multiple Myeloma", "Stage II Ovarian Epithelial Cancer", "Stage III Malignant Testicular Germ Cell Tumor", "Stage III Multiple Myeloma", "Stage III Ovarian Epithelial Cancer", "Stage IIIA Breast Cancer", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer", "Stage IV Breast Cancer", "Stage IV Ovarian Epithelial Cancer", "Testicular Choriocarcinoma", "Testicular Choriocarcinoma and Embryonal Carcinoma", "Testicular Choriocarcinoma and Seminoma", "Testicular Choriocarcinoma and Teratoma", "Testicular Choriocarcinoma and Yolk Sac Tumor", "Testicular Embryonal Carcinoma", "Testicular Embryonal Carcinoma and Seminoma", "Testicular Embryonal Carcinoma and Teratoma", "Testicular Embryonal Carcinoma and Teratoma With Seminoma", "Testicular Embryonal Carcinoma and Yolk Sac Tumor", "Testicular Embryonal Carcinoma and Yolk Sac Tumor With Seminoma", "Testicular Teratoma", "Testicular Yolk Sac Tumor", "Testicular Yolk Sac Tumor and Teratoma", "Testicular Yolk Sac Tumor and Teratoma With Seminoma" ], "interventions": [ { "name": "ipilimumab", "type": "DRUG" }, { "name": "therapeutic allogeneic lymphocytes", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2003-04", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-03-27", "last_synced_at": "2026-10-04T02:31:17.882Z", "location_count": 5, "location_summary": "La Jolla, California • Atlanta, Georgia • Boston, Massachusetts", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00060372" } ] }